Tianyun Accelerates to the Resumption of Full Production Capacity

Tianyun International Holdings Limited (“Tianyun International”, together with its subsidiaries, the “Group”, Stock code: 6836.HK), a leading seller and manufacturer of processed fruits products in China, is pleased to announce, upon the easing of the coronavirus disease 2019 (“COVID-19”) outbreak in China, to echo with the Government’s initiative of “Progressive Resumption of Production”, the Group’s production and operations have gradually resumed since late February. The Group’s production bases in China are expected to resume normal production capacity in April 2020 which is very encouraging. The Group will continue to work hard on ensuring the normal business development and achieving safe production.

To ensure the smooth and gradual resumption of production, the Group has setup an emergency leadership team for epidemic prevention and control and has implemented a series of prevention and strict control measures including the provision of adequate antiseptic and disinfection materials at all production lines. Under strict control measures, the Group recorded zero infection of COVID-19 among the entire workforce. The Group has also donated about RMB 300,000 in supplies and providing various appropriate aids for prevention and control for the epidemic.

Mr. Yang Ziyuan, Chairman and CEO of the Group, said, “Amid the uncertainties brought by the COVID-19, under the collaborative teamwork by the employees, Tianyun remains strong in fundamentals and has sufficient capacity to cope with the current unstable and complex environment. Tianyun International will respond positively to the challenge ahead, while doing our job of preventing and controlling the epidemic, we will accelerate the resumption of full production capacity and operations. We hope to maintain internal stability and actively take up our social responsibilities to assist recovery of economic and production activities in the society as soon as possible. “

About Tianyun International Holding Limited (Stock Code: 6863.HK)
Tianyun International Holdings Limited (the “Company”) and its subsidiaries (collectively referred to as the “Group”) are principally engaged in (i) the production and sales of processed fruit packaged in metal containers, plastic cups, glass containers and aluminium foil bags ii) trading of fresh fruit. Processed fruit products are sold both under our own brands and on an OEM basis.

The Group has been consistently committed to provide healthy and safe products to its customers. As one of the food enterprises with the most complete quality certifications, we have always been dedicated to following stringent international production standards and are accredited with BRC (A), IFS Food (High), FDA, HALAL, SC, KOSHER, BSCI and ISO22000 in respect of our production facilities, quality control and management. The Group has also passed the internal food production standard reviews and audits from some of the UK and US supermarket chains. At the same time, within China, as a “Equal production line; Equal standard; Equal quality” food production and export enterprise, the Group has been supplying products of equivalent quality to domestic and international markets. Since 2016, the Group’s own brand processed fruit products have continued to obtain a high degree of market recognition, and have been awarded by a national institution the honour and qualification of “China Canned Product Quality Certification Label”, become the first fruit processor in China’s fruit processing industry to put the “Zero Added Preservative Canned Products” label for its products sold in China.

The Group was awarded 2017 China’s Most Promising Listed Companies by the internationally renowned financial magazine Forbes and became the only integrated food production and sales enterprise in Linyi City, Shandong Province, which was awarded the “2017 Linyi Mayor Quality Award”. The Group’s newly researched and developed pure fruit snack food also received the “Certificate of Invention Patent” from the State Intellectual Property Office of the People’s Republic of China in 2018.

For more information, please visit www.tianyuninternational.com

Showa Denko to Commence Tender Offer for Shares in Hitachi Chemical Company, Ltd. (JP:4217)

TOKYO, Mar 23, 2020 – (JCN Newswire) – HC Holdings K.K., a wholly-owned subsidiary of Showa Denko K.K. (“Showa Denko”; TSE: 4004), (the “Tender Offeror”, collectively with Showa Denko, the “Tender Offerors”), as announced by the Tender Offerors in the “Announcement Regarding the Planned Commencement of Tender Offer for Shares in Hitachi Chemical Company, Ltd. (TSE: 4217)” as of December 18, 2019, decided on the same day, through the Tender Offeror’s representative officer, to acquire common shares (the “Target Shares”) of Hitachi Chemical Company, Ltd. (the “Target Company” listed on the First Section of Tokyo Stock Exchange, Inc. (the “Tokyo Stock Exchange”) under the code number 4217) through a tender offer (meaning a tender offer under the Financial Instruments and Exchange Act (Act No. 25 of 1948, as amended; the “Act”); the “Tender Offer”).

The Tender Offer is subject to the satisfaction (or waiver by the Tender Offeror) of certain conditions precedent; for example, the procedures and actions required under competition laws and other laws and regulations inside and outside Japan (Japan, China, South Korea, the United States, the European Union, and Taiwan) must be completed in order to commence the Tender Offer (for detailed information, please refer to (Note 1) of “(1) Outline of the Tender Offer” in “1. Purpose of the Purchase” below), and the Tender Offerors planned to commence the Tender Offer as soon as the conditions precedent are satisfied (or waived by the Tender Offeror), and aimed to commence the Tender Offer by approximately February 2020.

However, as announced by the Tender Offerors in the “Announcement Concerning Progress Towards the Tender Offer for Shares of Hitachi Chemical Company, Ltd. (Securities Code 4217)” as of February 28, 2020, it requires time for the completion of the procedures and actions required under competition laws in some countries, and due to that the commencement of the Tender Offer was expected to be in and after March 2020.

Since the Tender Offerors confirmed that all the conditions precedent have been satisfied, Showa Denko’s board of directors and the Tender Offeror’s representative officer decided today to commence the Tender Offer on March 24, 2020.

For further details, please refer to the full press release at:
www.sdk.co.jp/assets/files/english/news/2020/20200323_sdknewsrelease_e.pdf

About Showa Denko K.K.

Showa Denko K.K. (SDK; TSE:4004, ADR:SHWDY), a major manufacturer of chemical products serving heavy industry to electronics and computers. The Petrochemicals Sector provides cracker products such as ethylene and propylene, the Chemicals Sector provides industrial, high-performance and high-purity gases and chemicals for semicon and other industries, the Inorganics Sector provides ceramic products, such as alumina, abrasives, refractory/ graphite electrodes and fine carbon products. The Aluminum Sector provides aluminum materials and high-value-added fabricated aluminum, the Electronics Sector provides HD media, compound semiconductors such as ultra high-bright LEDs and rare earth magnetic alloys, the Advanced Battery Materials Department (ABM) provides lithium-ion battery components. For more information, please visit www.sdk.co.jp/english/.

Contact:

Showa Denko K.K., Public Relations Office, Tel: 81-3-5470-3235

The Legendary Christopher C. Lee Photography & Film of San Francisco

Starting from a meteoric rise to fame in San Francisco as an iconic fashion and street photographer, Christopher C. Lee has riveted the attention of photography lovers nationwide with the grand opening of his boutique photography studio, Christopher C. Lee Photography & Film. He is also renowned as a portrait photographer who is able to “bring out the soul” of his subjects, capturing them in timeless frames. Chris is the founder of Photomochi (https://www.photomochi.com), an acclaimed Bay Area production studio, the lead designer of streetwear label Troo Wear (https://www.troowear.com), and the top-selling author of “The Japan Book”, a cult classic travel photography book depicting the most beautiful locations of the island country.

On the corporate side, Christopher has provided quintessential photography and videography for projects involving Google, Microsoft, Dropbox, YouTube, and more, earning him the nickname as the “Crown Jewel Photographer of Silicon Valley”. His roots and reach span far greater than just being the media expert of the technology sector, however. He has photographed promotions for crystal jewelry brand Swarovski, as well as Australian luxury lingerie label, Honey Birdette. Christopher C. Lee is the leading San Francisco photographer for photography agency Snappr, bringing in hordes of clientele for the start-up. He is also well-known among the ranks of food photographers for Doordash and Forkable, photographing several tasty dishes for their menu. Experienced in car photography, he has previously photographed for Bring A Trailer as well as Porsche. His creative momentum and visual repertoire is endless and can be traced back to his drive for creative freedom.

Christopher believes in achieving the apex of photography not only through visual design, but through the power of empathy. He is renowned for his unique approach to the business strategy of a creative company for art professionals. Firmly focusing on a grassroots, freelancer perspective, his criteria for his team of elite production experts span many levels, usually on themes regarding their independence, positivity, and humanity. Upon joining the team, his professionals are welcomed with immediate social and financial support to see their vision through. Each professional is catered to with an individualized support network and personal space to create. This parameters are recognized and set during the interview process. He firmly establishes a professional connection based on mutual trust and empathy, allowing his staff to have full personal stake in their work. Though the bar is set high, his team at Christopher C. Lee Photography & Film, as well as Photomochi, has always delivered.

Notable projects include the viral music video for “Popout” (https://youtu.be/OmvL48okIFw), a hit single by Empire Distribution and Afficials artists $tupid Young and MB Nel, from their collaboration album “The Yellow Tape”. He has worked on the video promo Axent Wear, a designer headphone brand, gathering over 3 million dollars in funding as well as half a million views on it. He has provided photography services for top ranking blockchain organizations such as ETH San Francisco, photographing Vitalik Buterin, founder of Ethereum, and Balaji Srinivasan, CTO of Coinbase. Christopher’s reach spans an audience of millions through his meticulous work, and he is tirelessly committed to perfecting his craft.

All areas of pre-production – client consultations for project ideation, project treatments, location scouting and preparation, shot planning, set construction, talent acquisition, equipment rentals, are all done in-house and seamlessly so. Production comes in at full-force with a handpicked team of photographers, cinematographers, production assistants, set designers, wardrobe stylists, make-up artists, directors, assistant directors, producers, grips, and more, all up to the client’s specifications. Post-production covers everything from editing to visual effects to color grading to digital mastering of deliverables. They even offer marketing and promotional services as well.

Behind his hulking reputation as a photographer, Christopher C. Lee is known for being a genuine and kind professional amongst his creative peers. He is a solid team player and gives all of his employees the best shot at personal success. With his ability to lead a talented staff across all of his projects, nothing is impossible.

Contacts:

Photomochi
San Francisco Bay Area
Office: 1-415-212-9329
E-mail: showtime@photomochi.com
Website: https://www.photomochi.com

Christopher C. Lee
San Francisco Bay Area
Office: 1-415-289-9644
E-mail: contact@chrisclee.com
Website: https://www.chrisclee.com

The Impact of Hospitals on Accelerating the Spread of Coronavirus

TOKYO – (JCN Newswire) – Consultants at Azabu Insights wanted to understand the stark differences between mortality rates in Korea (currently 1.1%) and Italy (8.3%). We felt that current explanations suggested by virologists, while making a number of valid points, have ultimately been unsatisfactory.

Azabu Insights presents the hypothesis that hospitals may have been one of the breeding grounds for virus infection in Italy and this may have been one of the causes of the high mortality rates. This is a major concern, going forward, for other countries including the United States.

Azabu Insights recommends that policy experts and hospital management carefully consider existing practices to ensure that potential carriers of coronavirus can access to testing and appropriate treatment without spreading the virus to other persons in the healthcare facility. We think that the highly contagious nature of COVID-19 suggests a need for more isolated facilities and stricter measures than have been implemented, in many cases, thus far.

We urge that the successful policies implemented to curb the early outbreaks in China and Korea, including those around hospital isolation and safe testing, should be examined and implemented when appropriate.

Exploring Macro Drivers Behind Infection and Mortality

Previous articles have noted that many of those who died in Italy were older, male, and often smokers. Experts agree that these traits are key risk factors in severe COVID-19 infections (as they are for many other respiratory diseases). It has been argued that these attributes are reflective of broader Italian society, particularly citing Italy’s age profile, and by extension proving why Italy’s outbreak has been so deadly. We contrasted this with Japan and Korea, which share Italy’s characteristics of aging populations with high smoking rates and have also seen coronavirus outbreaks in recent weeks.

Firstly, we examined the key macro data. According to the World Bank, 23% of Italians are over the age of 65, making it the oldest nation in Europe. Note however, there are 16 European countries where at least 20% of the population is over 65, so Italy is by no means a large outlier. Compared with Italy, Korea is a little younger with 18% of its citizens over 65 however Japan is significantly older with 27% of its populace 65 or older. Digging a little further we see that in Cremona, one of the areas hit hard by the northern Italy outbreak, almost 33% of people were over the age of 60 compared with 38% over 60 in Japans Kitami, the site of Japans main outbeak. With regards to smoking, overall smoking rates are higher in Korea (24%) and Italy (22%) than in Japan (18%). However in Korea, men’s smoking rates are much higher at 34% than the 27% of Japanese males and the 23% of Italian men who currently smoke.

These numbers suggest that Japan and Korea, at best, both share similar risk factors to Italy and arguably look much poorer than their European counterpart. Given this, Azabu Insights asserts there are other factors that are driving the speed and intensity of the Italian outbreak.

Partly Result of Tested Populations

Part of the effect of the disparity can be accounted for by the disparity in tested populations. Korea has tested aggressively, with over 286 thousand people (second only to China’s 320 thousand) tested and 3% testing positive. They tested broadly across all age groups with 28% of test subjects 20-29 years old and 58% under the age of 50. In turn many of the younger Koreans tested positive for COVID-19. It should come as no surprise that the mortality rate would be lower amongst this group of younger people because younger people have a lower mortality risk from the outset.

Italians have conversely seen a high 21% of those tested, return positive COVID-19 results (seven times higher than Korea). This says to us that the people who received the tests may have been chosen differently. Perhaps, in Italy, they prioritized (as would make sense) testing of the old, those at risk and those with severe symptoms. We know that the survival rates decrease significantly over 70 and further after 80, so the widespread reports that most people who died were over 70 did not surprise us.

To state it simply: if you find a large number of positive cases among young people, who are not at risk, you would expect few of them to die. If you find a large number of positive cases amongst older at-risk people, you would expect more of them to die. It is an example of Bayess theorem.

But testing differences alone, likely do not account for the sheer numbers of deaths in Italy, which have now surpassed those in China.

Risk of Infection at Hospitals

At Azabu Insights we have interviewed hundreds of doctors face to face over the last five years. We travel to all corners of Japan to meet directly with doctors in their hospitals. A key observation, something that nearly everyone who visits a hospital should know by gut intuition: the primary demographic in a hospital is the elderly. Confirming the data we see that in Japan, 73% of all people in hospitals are 65 or above and 53% are 75 or above. We are confident that these percentages are likely similar in demographically comparable Italy and in many other parts of the world.

This leads to examination of testing procedures for highly infectious diseases. Korea’s testing regime, discussed earlier, has seen a number of novel and innovative solutions. It is possible to be tested for coronavirus in a drive through in just a few minutes. Other than the obvious convenience, this has the core benefit of not needing to walk through a hospital waiting room and risk infecting the other patients and the hospital staff.

In Japan interviews with the president and vice president of two major Japanese hospitals highlighted similar concerns. The first doctor was actively sending people with symptoms away from the hospital to get treated elsewhere. The second doctor had temporarily refused to see measles patients at his hospital. Both of these health practitioners did this to protect their own patients from in hospital spread.

In contrast we see that 10% of healthcare workers in the Lombardy region of Italy have contracted coronavirus. In one region, 20% of all GPs are confirmed to have coronavirus. In both cases, many of them are continuing to work given the well documented shortage of healthcare workers in Italy right now. On top of this, a study of 138 patients in Wuhan, China, suggests 41% of patients may have been victims of hospital-related transmission. This further suggests to us that hospitals are perhaps the worst place to be during a viral epidemic. Yet hospitals are hard to avoid for people in need of medical care. This is especially challenging for the elderly (age 75) who are 6.5 times more likely to be in a hospital than younger adults (age 35).

The SARS Effect on Treatment Patterns

We have extensively reviewed published data and studies, looked at various government recommendations, as well as examining popular published media outlets. In past outbreaks such as SARS, cases of asymptomatic spread were low and in-hospital spread was considered controllable through the use of masks and other standard procedures. In the case of coronavirus however we see clear evidence of both asymptomatic spread and spread from within the hospital system. However we believe that the role of asymptomatic spread and from within the hospital system remains significantly underestimated.

We believe that public policy and messaging in many countries is still largely based on previous outbreaks such as SARS and has failed to keep pace with the reality of how the coronavirus is spread. In contrast, China and Korea have adapted quickly and changed how they approach the management of this pandemic. In particular, they have shown that aggressive isolation of patients from the regular hospital system, including preventing congregation at test centers and separating coronavirus patients from regular patients in completely separate hospitals, can be an effective tool in controlling the spread of the coronavirus. We encourage policy makers in other countries, such as the US, to look to their example for ways to update their approach to better manage the current crisis.

Available Beds and Isolated Treatment Facilities

For patients that require treatment due to more severe coronavirus symptoms, the availability of physically separated treatment or in hospital isolation facilities is key to limit the hospital related transmission alluded to in the above paragraphs. We believe that China for example, did this very effectively by building two hospitals and acquiring gyms just to treat COVID-19 patients.

We examined available hospital capacity, with a focus on the ability to isolate and treat infectious disease. For standard hospital treatment, research shows that Japan is the most equipped globally with 13.4 beds per thousand people, followed by Korea with 11.5 beds per thousand people. This contrasts with most other developed countries which typically have anywhere from two to eight beds (2.9 in USA, 2.8 in UK, 3.4 in Italy) per thousand people. The real concern however is the number of beds that are available to treat highly infectious diseases. Taking conservative Japan as our baseline, we found that only 0.12% of all of Japan’s beds are set up for infectious diseases and 0.32% are tuberculosis certified.

We know from reports that 16% of people in Lombardy hospitals had coronavirus. We believe that its very likely that small hospitals in the countryside of Italy were over run with too many people that had the virus. Despite reports of operating rooms being turned into seclusion units on a best effort basis, we have serious concerns about the ability of the hospitals to limit the spread of coronavirus within their institutions. This can lead to the worst case scenario where the infected patients spread the disease both to healthcare workers and to other patients resulting in the deaths of the already at-risk patients. From this perspective we think that the typical concern of running out of respirators, though important, the earlier measures of keeping the patients from spreading the virus may be more important.

Next Steps and Best Practices

We believe that the risk of testing and of treating people in regular hospitals is being fully underestimated. We feel that hospitals overestimate their ability to keep the virus from spreading in their hospitals.

Our suggestion is that as the United States begins its testing and particularly as it ramps up, they should be extremely careful and learn from the experience of countries such as China and Korea. All testing should be conducted at designated locations that are not physically connected to hospitals where there are other patients. No patients should be allowed to congregate or wait.

An ideal situation would be one in which coronavirus patients could be treated in their own, completely separate hospitals, as has begun to happen in Northern Italy, and in parts of the United States, but, we feel, not broadly enough.

Further, the major hospitals must immediately decrease the number of people they treat. This goes for Japan as well, no longer should hospitals allow large waiting rooms filled with people. All non-essential procedures should be delayed. Again we have heard anecdotal reports of this occurring in the US and other countries already, but not universally.

In addition we recommend that any worker at a major hospital should be tested, at least for temperature, before going into hospitals and aged care facilities. Visitation, by people who may be asymptomatic carriers, should be severely limited. Everyone who goes into hospitals should wear masks, minimize touching and speaking, and should not be waiting in centers together.

Azabu Insights believes that these best practices should be implemented in conjunction with existing recommendations for limiting community spread including, but not limited to, hygiene and hand washing, wearing masks in public places if available, avoiding crowded places and working from home where possible.

About Azabu Insights

Azabu Insights is a boutique strategic consulting company based in Azabu Juban, Tokyo, Japan. Our teams work collaboratively with clients to build strategies that lead to positive change. Our multilingual team members have top tier academic backgrounds and deep industry experience that we leverage to provide first class, fully engaged, strategic consulting. Core specializations include life sciences, finance, electronics, automotive, aerospace and other industries. For more information contact: info@azabuinsights.com

Novotech CRO Tapped for Two Informa Citeline Awards for Excellence in Asia-Pacific Clinical Trials

SYDNEY – (ACN Newswire) – Asia-Pacific’s largest specialist biotech CRO Novotech has been selected as a finalist in two categories for the Citeline Awards 2020 (formerly CARE Awards), hosted by Informa Pharma Intelligence, scheduled this year on September 17th. The categories are Clinical Research Team of the Year, and Medidata Clinical Partnership of the Year.

Dr John Moller, Novotech CEO, said, “These are major milestones for the company, and further recognition of Novotech as the premier CRO in Asia-Pacific. We are particularly thrilled that the Medidata Clinical Partnership of the Year recognizes Novotech and its Chinese partner PPC, for excellence in clinical trial services in the Asia region.”

Karen Currie, Citeline Executive Director of Editorial, said: “We had a highly competitive pool of entries this year. Nominations were received from a variety of organizations, from large and small CROs to young biotechs and well-established pharmas, to specialized vendors who provide indispensable services to the clinical research industry. Attaining a position on a shortlist is a tremendous achievement and we extend our congratulations to all the finalists.”

Now in their fifth year, the Citeline Awards honor the accomplishments of those working behind the scenes in Clinical R&D, improving healthcare worldwide through the discovery and development of new drugs. The Citeline Awards focus on the people and companies inspiring the biopharm industry through tireless work, innovative thinking, and advances across Clinical R&D.

Currie said “Drug development is a challenging endeavor, and we are pleased and honored to celebrate the accomplishments of this distinguished group of R&D professionals at the upcoming awards ceremony.”

The winners will be chosen by a distinguished panel of independent judges.

View the full Citeline Awards shortlist here: https://tinyurl.com/rppo9hv.

About Informa Pharma Intelligence

Informa Pharma Intelligence powers a full suite of analysis products – Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, every key disease, clinical trial, drug approval and R&D project is covered by the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

About Informa PLC

Informa operates at the heart of the Knowledge and Information Economy. It is one of the world’s leading business intelligence, academic publishing, knowledge, and events businesses. With more than 6,500 employees globally, it has a presence in all major geographies, including North America, South America, Asia, Europe, the Middle East and Africa.

About Novotech

Novotech, established in 1996, is internationally recognized as the leading full-service contract research organization (CRO) in Asia-Pacific. Novotech provides clinical development services across all clinical trial phases and therapeutic areas and has been instrumental in the success of over a thousand Phase I – IV clinical trials for biotech companies.

Novotech obtained the ISO 27001, the best-known standard in the ISO family, providing the requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies. Visit http://novotech-cro.com.

For RFP enquiries, please fill in the form available at https://novotech-cro.com/talk-to-an-expert.

Media Contact

Kate Johnson

communications@novotech-cro.com

AU: +61 2 8218 2144

USA: +1 415 951 3228

Asia: +65 3159 3427

Australian CRO, Avance Clinical is Uniquely Positioned for COVID-19 Vaccines and Therapies Clinical Trials

Adelaide, AUS, Mar 20, 2020 – (ACN Newswire) – Australian CRO Avance Clinical said today that Australia’s fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials.

Avance Clinical offers 20-years of experience in the CRO sector, and has conducted vaccine and infectious diseases trials in the past 5 years. Avance is clearly the CRO of choice for trials targeting COVID-19.

“Importantly, the more than 40% R&D cash rebate from the Australian Government and the attractive current exchange rate, makes Australia one the most cost-effective destinations for conducting clinical trials,” said Avance Clinical CEO Yvonne Lungershausen.

Australia’s reputation for scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for current COVID-19 trials.

“Our depth of expertise and knowledge in the area makes us the CRO of choice for any biotech looking to develop treatments for COVID-19,” said Ben Edwards, Avance’s Chief Strategy Officer.

“It is also very important to emphasise that based on current trends, Australia is likely to be one of the countries least affected by COVID-19.

We anticipate that this sets the scene for the least amount of disruption to clinical trial activities over the period in which the world adjusts to the situation created by COVID-19.”

Ms Lungershausen said in general terms, we do not anticipate significant disruption to the progress and timelines for the projects we are currently managing across all therapeutics indications. “Our team’s experience in working with remotely based clients and clinical service providers and our virtual communication systems and processes place us in a clear position of strength in maintaining the momentum for our current projects,” she said.

“Our team is very much accustomed to remote communication and management of projects,” said Mr Edwards.

Clinical research sites in Australia have already responded to the challenges of the COVID-19 pandemic, putting measures and systems in place which aim to safeguard the interests of their patients and the general public, while also seeking to minimise disruption to clinical research activities.

The Avance Clinical operations team maintains constant communication with trial sites, receiving the latest information on ongoing changes in procedures and effectively managing the activities relating to the projects being managed by Avance.

“Avance Clinical has a range of tools available to support the sites and our clients to successfully complete their trials during this challenging time. These will be carefully managed to ensure study compliance,” said Ms Lungershausen.

For more information about the benefits of running your next study in Australia contact us: https://www.avancecro.com/contact-us/

About Avance Clinical

Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:

– Access to independent Phase 1 facilities across Australia including hospital-based units for critical care

– Dedicated Investigators committed to clinical research

– Major hospitals with world class infrastructures and dedicated Clinical Trial Units

– Expedited clinical trial start-up timeframes

Media Contact:

Media@AvanceCRO.com

Chris Thompson

Showa Denko Group to Mass-produce SPALF Packaging Materials for Large Onboard LIBs

TOKYO – (JCN Newswire) – Showa Denko Packaging Co., Ltd. (SPA), a consolidated subsidiary of Showa Denko K.K. (SDK; TSE:4004), has developed a new product to be added to the lineup of SPALF(TM) aluminum laminate films which are used as packaging material for pouch-type lithium-ion batteries (LIBs), and will install equipment to mass-produce the new product. This new product is specialized for large-sized LIBs, which are mainly used for cars. Operation of the new production equipment is scheduled to be started in March, 2021.

SPALF is laminated composite film consisting of resin films and aluminum foil, and is mainly used as packaging material for pouch-type LIBs. SPALF has a large global market share due to its excellent insulation performance and superb plasticity. Pouch-type LIBs have outstanding flexibility in shaping, and are used in many kinds of small devices including smartphones and tablets. Moreover, they are widely used in large-sized equipment including EVs because pouch-type LIBs’ high quality has been widely recognized and there has been considerable progress in verification of pouch-type LIBs’ safety. Since development of EVs is in progress not only in China but also in Europe and the demand for pouch-type LIBs has been increasing, this time the Showa Denko Group has developed a new type of SPALF for large-sized LIBs and decided to install equipment to mass-produce the new product.

The Showa Denko Group’s Vision is to make itself a “KOSEIHA Company” (a group of KOSEIHA Businesses that can maintain profitability and stability at high levels over a long period). The global demand for LIBs (in electrical capacitance) is expected to increase 30% a year until 2025. The Showa Denko Group produces and sells various LIB materials with distinguishing advantages, such as SPALF(TM), VGCF(TM) additives for anode/cathode materials, and POLYSOL(TM) aqueous binding resin. By increasing sales of these LIB materials, the Group will aim to contribute to the growth of LIB market and improvement in functions of LIBs, and make the Group’s LIB materials business grow to be established as a KOSEIHA Business in the field of advanced battery materials.

About Showa Denko K.K.

Showa Denko K.K. (SDK; TSE:4004, ADR:SHWDY), a major manufacturer of chemical products, serves a wide range of fields from heavy industry to electronics and computer industries. The Petrochemicals Sector provides cracker products such as ethylene and propylene, the Chemicals Sector provides industrial, high-performance and high-purity gases and chemicals for semicon and other industries, and the Inorganics Sector provides ceramic products, such as alumina, abrasives, refractory and graphite electrodes and fine carbon products. The Aluminum Sector provides aluminum materials and high-value-added fabricated aluminum, the Electronics Sector provides HD media, compound semiconductors such as ultra high-bright LEDs and rare earth magnetic alloys, and the Advanced Battery Materials Department (ABM) provides lithium-ion battery components. For more information, please visit www.sdk.co.jp/english/.

Contact:

Showa Denko K.K., Public Relations Office, Tel: 81-3-5470-3235

Cloud Expo Asia, Hong Kong Announces New Dates for its 2020 Events

HONG KONG – (ACN Newswire) – To ensure a safe and smooth exhibition experience amid the latest developments of the Novel Coronavirus (COVID-19) situation, the organiser of Cloud Expo Asia, Hong Kong — CloserStill Media has postponed the expo and its co-locating events, originally scheduled on 20-21 May to 23-24 September 2020 at the Hong Kong Convention and Exhibition Centre (HKCEC).

“Safety is a top priority for us. Due to signs of community spreading of the coronavirus within the city, and after extensive consultations with the Tech community, we believe running the events in September allows us the greatest chance of delivering a secure and vibrant platform for companies to do business,” said Ms Candice Wong, Event Director at CloserStill Media.

She added, “We seek the industry’s understanding and support for this decision, and would also like to take this opportunity to thank all our sponsors, partners, and speakers for their continuous support and commitment to work with us for the best possible outcome — to make the tech industry thrive amid current challenges!”

Cloud Expo Asia, Hong Kong will closely monitor the coronavirus situation in collaboration with the government, health authorities and Hong Kong Convention and Exhibition Centre, to ensure a high level of hygiene and safety at the world-class fairground in September. The team will be in touch with all confirmed sponsors and partners to discuss their participation at the postponed events. For urgent assistance, please email Candice.wong@closerstillmedia.com.

About Cloud Expo Asia, Hong Kong

Celebrating its 5th year milestone, Cloud Expo Asia, Hong Kong and its co-locating events serve as one of the most important platforms for Asia’s tech community to conduct business, network and generate lively discussions around the latest cutting-edge technologies. Embracing the entire tech ecosystem from Cloud, Cybersecurity, Big Data & AI, IoT, Data Centre to e-Commerce, this is where the tech community comes together to shape the next big wave of innovations.

Learn more at www.cloudexpoasiahk.com.

About CloserStill Media

CloserStill Media specialises in international professional events chiefly in the technology markets, across five global territories. Its portfolio includes some of the UK’s fastest-growing and award-winning events including Cloud Expo Europe and Data Centre World. Having delivered unparalleled quality and relevant audiences for all its exhibitions, CloserStill has been repeatedly recognised as a leading innovator with its teams and international events winning multiple awards in Europe and Asia including Best Marketing Manager — four times in succession — Best Trade Exhibition, Best Launch Exhibition, and Rising Star — two years in succession — among others.

For more information, visit www.closerstillmedia.com.

Media Contact:

Winnie Ho

Marketing Manager

+852-2972 0628

Winnie.ho@closerstillmedia.com

Asia Allied Infrastructure Concludes HK$1.25 Billion 3-year Term Loan Agreement

Solid business foundation in Hong Kong;
Winning long-term trust and support from banking community

Asia Allied Infrastructure Holdings Limited (“Asia Allied Infrastructure” or “the Group”) (stock code: 00711) is pleased to announce today that it has entered into a HK$1.25 billion term loan agreement with 5 banks. Part of the loan will be used to restructure the loan portfolio of the Group, while the rest will be used to support future operations and development. This facility will lower the overall finance cost of the Group, enhance its financial flexibility and funding capability.

The 3-year facility of HK$1.25 billion carrying an interest rate of HIBOR+1.65% was arranged by The Hongkong and Shanghai Banking Corporation Limited, China Construction Bank (Asia) Corporation Limited, CMB Wing Lung Bank Limited, Chong Hing Bank Limited and The Bank of East Asia, Limited.

Mr. Dominic Pang, Chairman of Asia Allied Infrastructure, said, “We would like to express our sincere gratitude to the banks for their trust and support to AAI. The new loan facility shows the banking community’s confidence in the Group’s solid business strategies in recent years. Though operating environment remains challenging due to factors including the recent outbreak of the coronavirus, we are confident that our long established business foundation will enable us to overcome these challenges. Building on AAI’s industry experience and a healthy financial position, we will continue to actively pursue set business strategies to capture market opportunities, enhance stakeholder value and delivery satisfactory returns to shareholders.”

Asia Allied Infrastructure Holdings Limited (stock code: 00711.HK)
Asia Allied Infrastructure Holdings Limited (“Asia Allied Infrastructure”) is listed on the Main Board of the Hong Kong Stock Exchange under stock code 00711. The Group operates businesses such as construction engineering and management, construction consultancy, property development and assets leasing, security and facility management, tunnel management, construction financing, premium safe deposit box leasing as well as an online construction materials procurement and management platform and a quality international education platform. Its subsidiary Chun Wo is a renowned construction contractor and property developer in Hong Kong. Chun Wo’s solid construction experience and professional capabilities have enabled the Group to seize suitable development opportunities, allowing the Group to enhance its overall profitability and investment value.

For press enquiries:
Strategic Financial Relations Limited
Cindy Lung (852) 2864 4867 cindy.lung@sprg.com.hk
Carven Tsui (852) 2864 4859 carvensm.tsui@sprg.com.hk
Desiree Shung (852) 2114 2200 desiree.shung@sprg.com.hk

Indonesia’s State-owned Hospitals Prepare Isolation Rooms as COVID-19 Cases Up

JAKARTA – (ACN Newswire) – State-owned hospitals, under the Indonesian Healthcare Corporation (IHC) Pertamedika, will help the government handle the spread of coronavirus (COVID-19), including through treating and isolating patients at their facilities, State-Owned Enterprises Minister Erick Thohir stated.

“There are in all 65 state-owned hospitals, with special treatment rooms and 155 beds, and 66 safe houses,” he noted in a statement received in Jakarta, Monday. He made the statement during a visit to the Pertamina Jaya Hospital in Jakarta on Thursday (Mar 12).

The number of people infected with COVID-19 in Indonesia continues to grow, with government spokesperson for COVID-19 handling, Achmad Yurianto, declaring that 117 had confirmed positive for the virus in Indonesia as of 5 a.m. local time on Monday (Mar 16).

Minister Thohir expressed confidence in the hospitals, under the state-owned facilities’ network, and their abilities to offer treatments to those diagnosed with COVID-19.

“I am very confident. They can also provide better treatment than those offered at private hospitals, as we focus on serving the people rather than on mere business profits,” he stated.

IHC Pertamedika comprises 65 hospitals located across Indonesia. Four facilities in Jakarta and Banten, include the Central Pertamina hospital, Krakatau Medika hospital, Pertamina Jaya hospital, and Pelni hospital.

Meanwhile, Central Java and East Java are home to the PHC hospital in Surabaya, Lavalette hospital in Semarang, Cirebon hospital, and Cilacap hospital.

The 12 hospitals located in Sumatra include the Plaju hospital in South Sumatra, Bakti Tuman Muntok hospital in Bangka Belitung, Prima Inti Medika hospital in Aceh, and Pangkalan Brandan hospital in North Sumatra.

Meanwhile, Kalimantan houses five health facilities: the Balikpapan hospital, Tanjung hospital and Danau Salak hospital in South Kalimantan, Parindu hospital in West Kalimantan, and Tarakan hospital in North Kalimantan.

In the eastern part of the country, an IHC Pertamedika hospital is located in Sorong, West Papua, with the Sorong hospital.

Director of IHC Pertamedika Dr. Fathema Djan Rachmat had informed ANTARA recently that apart from isolation rooms with negative pressure, she had prepared standard operational procedures for the treatment of patients under observation for COVID-19.

Rachmat also spoke of IHC Pertamedika having developed a tracking system to find potential cases.

“Indonesia stands united against this pandemic, so we need to develop a tracking system to identify patients or people under surveillance,” she explained. — Antara.